Skip to main content
Clinical Trials/NL-OMON39548
NL-OMON39548
Completed
Not Applicable

Feasibility study of biomarker development for response prediction by large scale DNA mutational analysis of metastatic lesions. - CPCT - 01 trial

niversitair Medisch Centrum Utrecht0 sites80 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
metastatic cancer
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
80
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • Metastatic colorectal carcinoma or other solid tumors
  • Failed at least one line of palliative chemotherapy
  • Irinotecan naïve
  • Eligible, as per local protocol, for palliative treatment with standard of care irinotecan
  • Measurable metastatic lesion(s) according to RECIST 1\.1\. criteria
  • Safe biopsy of a radiological measurable lesion possible
  • Adults age 18 years or up
  • Written informed consent

Exclusion Criteria

  • Patients with other malignancies than metastatic colorectal cancer or other solid tumors
  • Patients eligible for first\-line treatment
  • Patients who were already subjected to treatment with irinotecan
  • Patients with disease not measurable according to RECIST 1\.1\. criteria
  • Safe biopsy of radiological measurable lesion not possible
  • Patients younger than 18 years old
  • Patients not willing to sign informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials